These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8222793)

  • 21. Efficacy and tolerance of cefpodoxime proxetil compared with co-amoxiclav in the treatment of exacerbations of chronic bronchitis.
    Periti P; Novelli A; Schildwachter G; Schmidt-Gayk H; Ryo Y; Zuck P
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():63-9. PubMed ID: 2292532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical evaluation of cefpodoxime proxetil in the treatment of skin and soft tissue infections. A double blind comparison of cefpodoxime proxetil and cefaclor].
    Yura J; Shinagawa N; Mizuno A; Watanabe S; Ando M; Sakai K; Ueda T; Morimoto K; Nakamura T; Hashimoto I
    Jpn J Antibiot; 1988 Oct; 41(10):1517-37. PubMed ID: 3060626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cefpodoxime proxetil: dosage, efficacy and tolerance in adults suffering from respiratory tract infections.
    Safran C
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():93-101. PubMed ID: 2292535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microbiological evaluation of cefpodoxime proxetil.
    Wiedemann B; Luhmer E; Zühlsdorf MT
    Drugs; 1991; 42 Suppl 3():6-12. PubMed ID: 1726210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cefpodoxime proxetil in the treatment of skin and soft tissue infections.
    Tack KJ; Wilks NE; Semerdjian G; Frazier CH; Shirin K; Puopolo A; Crossland SG; Goffe BS; Millikan L
    Drugs; 1991; 42 Suppl 3():51-6. PubMed ID: 1726208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical evaluation of cefpodoxime proxetil on the treatment of bacterial infections].
    Li JT; Hou J; Kao L
    Zhonghua Nei Ke Za Zhi; 1994 Jul; 33(7):440-3. PubMed ID: 7867436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [RU 51807 (cefpodoxime proxetil). In vitro and in vivo antibacterial activity of a new orally administered active cephalosporin].
    Chantot JF; Mauvais P
    Pathol Biol (Paris); 1991 Jan; 39(1):17-27. PubMed ID: 1901403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of acute maxillary sinusitis in adults. Comparison of cefpodoxime-proxetil and amoxicillin-clavulanic acid].
    Polonovski JM; El Mellah M
    Presse Med; 2006 Jan; 35(1 Pt 1):33-8. PubMed ID: 16462661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical evaluation of cefpodoxime proxetil in patients with dermatological infections.
    Imaizumi T; Ishikawa H; Hashimoto I
    J Chemother; 1995 Nov; 7 Suppl 4():137-41. PubMed ID: 8904135
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten.
    Schatz BS; Karavokiros KT; Taeubel MA; Itokazu GS
    Ann Pharmacother; 1996 Mar; 30(3):258-68. PubMed ID: 8833562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cefpodoxime proxetil in upper respiratory tract infections.
    Bergogne-Berezin E
    Drugs; 1991; 42 Suppl 3():25-33. PubMed ID: 1726205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of once-daily cefpodoxime regimens against Haemophilus influenzae and Streptococcus pneumoniae with an in vitro pharmacodynamic chamber model.
    Garrison MW; Malone CL; Eiland JE
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1545-7. PubMed ID: 8726036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparative antibacterial activity of cefpodoxime against Haemophilus influenzae, Streptococcus pyogenes, Streptococcus pneumoniae and Moraxella catarrhalis].
    Wallrauch-Schwarz C; Milatovic D; Braveny I
    Arzneimittelforschung; 1994 May; 44(5):668-70. PubMed ID: 8024645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical trials of cefpodoxime proxetil suspension in paediatrics.
    Fujii R
    Drugs; 1991; 42 Suppl 3():57-60. PubMed ID: 1726209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antibacterial activity of cefpodoxime against clinical isolates in 2000 and 2001].
    Abe T; Fukuoka T; Sato Y; Ito K; Sei M
    Jpn J Antibiot; 2002 Dec; 55(6):827-43. PubMed ID: 12621736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microbiological and clinical studies on cefpodoxime proxetil for bacterial skin and soft tissue infections in pediatric patients.
    Ito K; Ito M
    J Chemother; 1995 Nov; 7 Suppl 4():124-6. PubMed ID: 8904131
    [No Abstract]   [Full Text] [Related]  

  • 37. Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women.
    Kavatha D; Giamarellou H; Alexiou Z; Vlachogiannis N; Pentea S; Gozadinos T; Poulakou G; Hatzipapas A; Koratzanis G
    Antimicrob Agents Chemother; 2003 Mar; 47(3):897-900. PubMed ID: 12604518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic and tolerance studies of cefpodoxime after single- and multiple-dose oral administration of cefpodoxime proxetil.
    Borin MT; Hughes GS; Patel RK; Royer ME; Cathcart KS
    J Clin Pharmacol; 1991 Dec; 31(12):1137-45. PubMed ID: 1761737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In-vitro activity of cefpodoxime proxetil (RU 51807): a comparative disk diffusion study on isolates from geriatric patients.
    Ottomano C; Frugoni S; Berlusconi A; Miseferi G; Mattina R; Anelli M
    J Chemother; 1991 Jan; 3 Suppl 1():62-5. PubMed ID: 12041788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clarithromycin versus cefaclor in lower respiratory tract infections. The Canadian Bronchitis Study Group.
    Fong IW; Laforge J; Dubois J; Small D; Grossman R; Zakhari R
    Clin Invest Med; 1995 Apr; 18(2):131-8. PubMed ID: 7788958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.